Alberta is emerging as a global leader in theranostics and radiopharmaceutical science, driven by the work of Dr. Frank Wuest at the Cross.
For nearly two decades, Dr. Frank Wuest has led research to develop new medical isotopes and radiopharmaceuticals that strengthen how cancer is diagnosed and treated. His work focuses on theranostics, a field that links diagnostic imaging with targeted therapy to help clinicians see cancer more clearly and treat it more precisely.
“Through our research, we are able to introduce the next generation of targeted therapies,” says Wuest. “Improving patient care by individualizing it.”
The impact of this work now extends far beyond Alberta. These rare research tools are being shared with collaborators across Canada and internationally, supporting studies in the United States, Europe, Asia and Australia.
“We are so proud of this accomplishment,” Wuest reflects. “It puts Edmonton at the forefront of this research.
Dr. Wuest’s leadership in this field is helping establish Alberta as a global hub for theranostics and radiopharmaceutical innovation.
“Donor generosity made it possible to build something truly exceptional. This is an area of science with enormous potential, and that investment is paying dividends for patients worldwide,” says Wuest.
In 2025, this work reached a major milestone. Wuest’s team successfully produced new radioisotopes, including Lead-203, strengthening the precision of cancer diagnosis and treatment. These isotopes help researchers and clinicians locate cancer more accurately, supporting earlier detection and more targeted therapies.
